Welcome to our dedicated page for Treatment.com AI news (Ticker: TREIF), a resource for investors and traders seeking the latest updates and insights on Treatment.com AI stock.
Treatment.com AI Inc. (TREIF) is a pioneering force in AI-driven healthcare solutions, merging clinical expertise with advanced technology to transform medical education and diagnostic support. This page serves as the definitive source for official company announcements, strategic developments, and milestone updates.
Investors and healthcare professionals will find curated news on TREIF's Global Library of Medicine (GLM) advancements, Medical Education Suite (MES) implementations, and partnerships shaping AI integration in clinical environments. Key updates include product launches, clinical validation milestones, and collaborations with medical institutions.
Our repository provides immediate access to earnings reports, technology licensing agreements, and regulatory filings. All content is vetted for accuracy, offering reliable insights into TREIF's role in reducing diagnostic errors and streamlining medical training processes through AI innovation.
Bookmark this page for real-time updates on TREIF's contributions to healthcare technology. For comprehensive tracking of the company's progress in AI-powered clinical decision tools and educational solutions, revisit regularly or subscribe to alerts.
Treatment.com AI (CSE: TRUE, OTC: TREIF) reported significant success with its Rocket Doctor platform's Emergency Department (ED) diversion program. At Georgian Bay General Hospital, the program has successfully managed over 3,065 patients between June 2022 and December 2024, with 97.5% handled virtually and only 1% requiring ED redirection.
The program has generated estimated savings of $1.4 million, based on an average cost of $475 per diverted ER visit. In Alberta, the platform has facilitated 12,000+ patient visits in the last three months, with 98% resolved virtually and less than 1% requiring ED visits. The solution combines smart triage, provider infrastructure, and AI-enabled care to address Canada's emergency department crisis, particularly impacting rural communities.
Treatment.com AI (OTC: TREIF) has announced that its subsidiary, Rocket Doctor, is partnering with EngageWell IPA to launch the Healthy Aging Program, backed by a $1 million, 5-year grant from the CVS Health Foundation. The program offers virtual health screenings for adults aged 60+ across New York City.
The initiative provides free virtual assessments for heart health, memory, cognitive function, and mental health, conducted by board-certified physicians. Participants can receive up to $45 in gift cards upon completion. The service is free for Medicaid patients and covered by insurance for Medicare patients. The program includes support from Community Health Workers who assist with telehealth connections and follow-up care coordination.
Treatment.com AI (OTC: TREIF) reports significant progress following its acquisition of Rocket Doctor, showcasing strong growth metrics and strategic achievements. Rocket Doctor's patient volume surged 112% year-over-year in Alberta, serving over 36,000 patients in 2024, while physician adoption grew by 218% from 22 to 70 active physicians.
Key developments include partnerships with Central California Alliance for Health (450,000-member managed care plan) and Melanoma Canada, plus the deployment of their Medical Education Suite at the University of Minnesota Medical School, potentially reducing exam costs by 40%. The company received recognition as Top Clinical Innovator by the American Telemedicine Association and secured positions in prestigious programs including UC Berkeley Health Engine Accelerator and AARP AgeTech Accelerator.
Treatment.com AI (CSE: TRUE, OTC: TREIF) and its virtual care platform, Rocket Doctor, have received recognition from three prestigious healthcare innovation organizations. The company was selected for UC Berkeley's Health Engine non-dilutive accelerator program for high-impact healthcare startups. At Harvard University, CEO Dr. William Cherniak was invited to speak about Rocket Doctor's transformation of healthcare delivery through virtual care, AI, and connected devices. Additionally, at the AARP AgeTech Conference, Dr. Cherniak presented the company's approach to improving care for Medicaid and Medicare patients.
These recognitions follow Rocket Doctor's recent award as Clinical Innovator of the Year at the American Telemedicine Association's NEXUS 2025 Innovators Challenge. The company focuses on using technology to reduce barriers to care and streamline access for underserved populations.
Treatment.com AI Inc. (CSE: TRUE, OTC: TREIF) announced that its virtual care subsidiary, Rocket Doctor, has partnered with Melanoma Canada to provide follow-up care for patients identified as at-risk during mobile skin cancer screenings. The partnership will facilitate direct referrals to Rocket Doctor physicians through a digital intake process for patients without family doctors across Ontario, Alberta, and British Columbia.
The collaboration involves Melanoma Canada's Mole Mobile units, which offer free skin cancer screenings in remote and urban communities. The initiative addresses a critical healthcare need, as skin cancer represents 1 in 3 cancer diagnoses in Canada, with 22 Canadians diagnosed with melanoma daily. The 12-month agreement, starting February 3, 2025, includes branding opportunities on Mole Mobile vans and campaign materials.